Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
ISBN-13:
9780309151290
ISBN-10:
0309151295
Edition:
Illustrated
Author:
Institute of Medicine, Food and Nutrition Board, Board on Health Sciences Policy, Board on Health Care Services, Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease, John R. Ball, Christine M. Micheel
Publication date:
2010
Publisher:
National Academies Press
Format:
Paperback
334 pages
FREE US shipping
Book details
ISBN-13:
9780309151290
ISBN-10:
0309151295
Edition:
Illustrated
Author:
Institute of Medicine, Food and Nutrition Board, Board on Health Sciences Policy, Board on Health Care Services, Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease, John R. Ball, Christine M. Micheel
Publication date:
2010
Publisher:
National Academies Press
Format:
Paperback
334 pages
Summary
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease (ISBN-13: 9780309151290 and ISBN-10: 0309151295), written by authors
Institute of Medicine, Food and Nutrition Board, Board on Health Sciences Policy, Board on Health Care Services, Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease, John R. Ball, Christine M. Micheel, was published by National Academies Press in 2010.
With an overall rating of 4.0 stars, it's a notable title among other
books. You can easily purchase or rent Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease (Paperback) from BooksRun,
along with many other new and used
books
and textbooks.
And, if you're looking to sell your copy, our current buyback offer is $0.4.
Description
Many people naturally assume that the claims made for foods and nutritional supplements have the same degree of scientific grounding as those for medication, but that is not always the case. The IOM recommends that the FDA adopt a consistent scientific framework for biomarker evaluation in order to achieve a rigorous and transparent process. Table of ContentsFront MatterSummary1 Introduction2 Review: Evaluating and Regulating Biomarker Use3 The Biomarker Evaluation Process4 Case Studies5 Strengthening Evidence-Based RegulationAcronymsGlossaryAppendix A: Table of Papers About Biomarker QualificationAppendix B: Recommendations from Related IOM ReportsAppendix C: Committee Member and Consultant BiographiesAppendix D: Staff BiographiesAppendix E: Workshop AgendaAppendix F: Speaker Biographies
We would LOVE it if you could help us and other readers by reviewing the book
{user}
{createdAt}
{truncated_title}
{author_block}
by {truncated_author}
